Department of Oncology, Molecular Biotechnology Center, University of Torino, Italy.
Mol Oncol. 2024 Feb;18(2):241-244. doi: 10.1002/1878-0261.13601. Epub 2024 Feb 2.
Drug resistance represents a major limitation to the long-term efficacy of anti-cancer treatments. The commonly accepted view is that the selection of inheritable genetic mechanisms governs the development of secondary resistance. However, compelling evidence suggests an important role for adaptive cell plasticity and non-genetic mechanisms in the development of therapy resistance. The two phenomena are not mutually exclusive and the interplay between genetic and non-genetic mechanisms may affect tumor evolution during treatment. A broader characterization of the genetic and non-genetic mechanisms of drug resistance may pave the way for more precise and effective therapeutic strategies to overcome resistance.
耐药性是抗癌治疗长期疗效的主要限制因素。人们普遍认为,可遗传的遗传机制选择决定了继发耐药的发展。然而,令人信服的证据表明,适应性细胞可塑性和非遗传机制在耐药性的发展中起着重要作用。这两种现象并不相互排斥,遗传和非遗传机制之间的相互作用可能会影响治疗过程中的肿瘤进化。对耐药性的遗传和非遗传机制进行更广泛的描述,可能为克服耐药性的更精确和有效的治疗策略铺平道路。